Skip to main content
. Author manuscript; available in PMC: 2018 Jun 6.
Published in final edited form as: Cancer Cell. 2012 Sep 11;22(3):373–388. doi: 10.1016/j.ccr.2012.07.016

Figure 7. Docetaxel-Resistant Prostate Cancer Cells Have High Tumor-Initiating Capacity.

Figure 7

(A) Tumor incidence, T-IC frequency, and latencies 36 weeks after injection of limiting dilutions of parental and Docetaxel-resistant cells.

(B) Tumor incidence, T-IC frequency, and latencies 38 weeks after injection of limiting dilutions of DU145 and 22RV1 HLAI-sorted cells.

(C) Image of a mouse bearing tumors after injection of DU145 HLAI− cells in the upper flanks and HLAI+ cells in the lower flanks. H&E and immunofluorescence of indicated proteins in representative tumor xenografts generated from DU145 and 22RV1 HLAI− cells. White arrows point to CK− cells with positive nuclear staining of transcription factors and lack of HLAI and AR.

(D) Table summarizes prostate cancer patients' clinicopathological characteristics, tumor incidence, T-IC frequency, and latencies after 61 weeks of injection of limiting dilutions of HLAI-sorted cells from fresh human prostate cancer samples.

(E) H&E and immunofluorescence analysis of indicated proteins in human tumors and primary and secondary xenografts generated from HLAI− cells. Patient 9 is represented. White arrows point to CK− cells with nuclear expression of transcription factors and lack of HLAI and AR.

(F) Tumor incidence and latencies 24 weeks after injection of 100 HLAI−-sorted cells from prostate cancer xenografts treated with DMSO, Dexamethasone 15 mg/kg/i.p. daily, Cyclopamine 50 μg/kg/sc daily plus dexamethasone, DBZ 10 μM/kg/i.p. daily for 15 days every 4 weeks plus Dexamethasone, or with triple combination. Data is represented as means ± SD. *p < 0.05.

See also Figure S7 and Table S2.